688639 华恒生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)8.17327.15424.03020.11328.210
总资产报酬率 ROA (%)3.53814.97518.28115.17718.574
投入资产回报率 ROIC (%)4.42018.74422.26718.62620.205

边际利润分析
销售毛利率 (%)31.59740.51638.65932.33041.192
营业利润率 (%)16.08126.35924.11119.53127.165
息税前利润/营业总收入 (%)16.94526.28023.70319.97530.203
净利润/营业总收入 (%)14.56323.04122.51017.63324.854

收益指标分析
经营活动净收益/利润总额(%)88.58296.89795.15488.74581.659
价值变动净收益/利润总额(%)-0.0310.5032.1833.4310.000
营业外收支净额/利润总额(%)0.657-0.9150.2742.3295.416

偿债能力分析
流动比率 (X)0.5850.6262.2204.6611.618
速动比率 (X)0.4540.4911.8714.0801.327
资产负债率 (%)59.18854.01626.90819.74034.071
带息债务/全部投入资本 (%)44.21336.982-0.233-4.042--
股东权益/带息债务 (%)114.863156.433-38,972.633-2,358.525-3,087.138
股东权益/负债合计 (%)69.06785.190271.431406.598193.508
利息保障倍数 (X)22.361164.477-50.050-919.20420.358

营运能力分析
应收账款周转天数 (天)45.73547.00355.34349.8600.000
存货周转天数 (天)63.45556.51250.00042.7430.000